Share on StockTwits

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) COO Russell J. Cox unloaded 2,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $155.00, for a total transaction of $310,000.00. Following the completion of the sale, the chief operating officer now directly owns 57,032 shares of the company’s stock, valued at approximately $8,839,960. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 3.50% during mid-day trading on Tuesday, hitting $148.12. 1,084,347 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 52-week low of $66.43 and a 52-week high of $176.60. The stock’s 50-day moving average is $139.7 and its 200-day moving average is $141.. The company has a market cap of $8.797 billion and a price-to-earnings ratio of 116.73.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.61 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter last year, the company posted $1.37 earnings per share. Jazz Pharmaceuticals plc -’s revenue was up 25.8% compared to the same quarter last year. Analysts expect that Jazz Pharmaceuticals plc – will post $8.07 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Friday. They now have a $157.00 price target on the stock. Separately, analysts at JMP Securities initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 17th. They set an “outperform” rating and a $179.00 price target on the stock. Finally, analysts at Wells Fargo & Co. initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 10th. They set an “outperform” rating on the stock. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $171.50.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.